StemMed Cancer is a renowned brand that specializes in pharmaceutical testing and development. They offer a wide range of products and services to cater to the needs of cancer research. StemMed Cancer is committed to providing state-of-the-art pre-clinical drug testing services using patient-derived xenograft (PDX) models of breast and pancreatic cancers.

Their PDX models are developed from a diverse patient population and cover all clinically-defined subtypes of breast cancer, including estrogen receptor positive (ER+), HER2+, and triple-negative cancers. StemMed Cancer also excels in in vivo drug testing assays using PDX models. They have extensive experience in customizing studies to meet your experimental goals, whether it's a dose-response assay in a single PDX or a full-scale animal clinical trial involving multiple PDX models.

For reliable and accurate cancer drug testing, StemMed Cancer is the brand you can trust. Contact StemMed Cancer today to learn more about their innovative solutions and ways they can assist you in your research